1.1Acetate buffer for nasal liquid
The ratio of acetic acid to sodium acetate sets the pH, and their combined concentration sets the buffer capacity. A metered nasal pump dispenses the solution through a spray nozzle.
Generated automatically. Not reviewed by a person. Not legal advice or an opinion.
Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.
The ratio of acetic acid to sodium acetate sets the pH, and their combined concentration sets the buffer capacity. A metered nasal pump dispenses the solution through a spray nozzle.
A sealed foil blister limits moisture uptake during storage. At delivery, an air pulse disperses the powder into the nasal cavity, where nasal fluid dissolves deposited particles.
A thin water-soluble cellulose film contains epinephrine and citrate dispersed through its matrix. Nasal fluid hydrates the film and releases the dissolved ingredients at the contact surface.
A shallow cup with a fixed pouring lip holds the liquid dose. Tilting the cup directs the solution over the lip and into the nostril.
Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.
A veterinary bench fixture holds a cast model of a canine nasal cavity with a removable collection liner. A cradle seats a unit-dose device containing epinephrine and a citrate and aligns its nozzle with the model nostril. A mechanical lever actuates the device, and a rinse of the liner provides a sample for measuring epinephrine deposition.
A sealed aluminum laminate blister replaces a rigid dose reservoir and contains a unit dose of epinephrine and a citrate. The blister seats between a hand-compressed bellows and the nasal nozzle. The first part of the actuator stroke pierces the blister at its inlet and outlet, and the rest of the stroke drives air through the blister to carry the powder into the nasal cavity.
A bench fixture holds a nasal cavity replica and a unit-dose device containing epinephrine and a citrate. A pivot through the replica nostril positions the nozzle at 0, 15, or 30 degrees relative to the fixture horizontal while a collar maintains a 5 mm insertion depth. The operator actuates a fresh device at each setting and collects powder from the replica for deposition measurements.
A wall-mounted emergency supply cabinet holds individually pouched intranasal devices in spring-fed slots. Each device contains a unit dose of epinephrine and a citrate, and a front gate releases one pouch when the cabinet handle is pulled. A door switch records cabinet opening, and the user removes the device from its pouch and actuates it at the nostril.
An infrared emitter and photodiode face each other across opposed windows in the outlet channel of a unit-dose nasal device containing epinephrine and a citrate. A switch at the end of the actuator stroke triggers a controller to sample the photodiode signal. The controller logs the stroke and the transient drop in transmitted light as separate events, while the powder continues through the nozzle into the nasal cavity.
An indexed conveyor carries dose cartridges through tare weighing, powder filling, gross weighing, and sealing stations. A controller associates both weights with the same conveyor pocket and subtracts the tare from the gross weight to determine the fill mass of epinephrine and citrate powder. A pneumatic gate diverts cartridges outside the configured mass limits, and cartridges within the limits proceed to sealing and installation in intranasal devices.
A formed foil cavity holds one premeasured powder dose and a heat-sealed foil lid closes it. The blister sits in the nasal device between an air inlet and the nozzle passage.
An aqueous epinephrine salt solution contains dissolved citric acid and sodium citrate. The ratio of the acid to its salt sets the solution pH.
Pressing a thumb button drives a piston through a sealed air chamber. The displaced air passes through the powder reservoir and carries particles out through the nasal tip.
A plunger moves through a fixed stroke and displaces the contents of a prefilled liquid chamber. The liquid enters tangential channels in a swirl nozzle and exits as a spray of droplets.
Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.
Also provided are devices adapted for nasal delivery of a pharmaceutical formulation to a patient, including single, bi- and multidose delivery comprising a therapeutically effective amount of epinephrine and pharmaceutically acceptable salts thereof.A · US 2019/0269781 A1 · ¶ 81
Pharmaceutical formulations are applied directly to the nasal cavity using the devices described herein. In the case of a spray, this may be achieved for example by means of a metering atomizing spray pump, e.g. a single, bi-dose or multiuse spray device, with or without a propellant.A · US 2019/0269781 A1 · ¶ 398
After intranasal administration, the following mean exposures (AUC0-t) are observed.B · US 10,729,685 B2 · ¶ 53
An empty cell means only that no passage was reproduced there.
A need exists for needle-free and non-invasive methods of dosing epinephrine.A · US 2019/0269781 A1 · ¶ 3
Disclosed herein are methods, pharmaceutical formulations of epinephrine and methods of use thereof in the treatment of conditions such as type-1 hypersensitivity reactions (systemic allergic reaction), asthma, and cardiac arrest.A · US 2019/0269781 A1 · ¶ 4
There is a need in the art for pharmaceutical compositions which minimize the ability for abuse, and when administered properly, provide an adequate and effective amount of drug.B · US 10,729,685 B2 · ¶ 3
It is an object of the present invention to provide a pharmaceutical composition that reduces the potential for improper administration drugs but which, when administered as directed through oral administration, is capable of delivering a therapeutically effective dose to a subject.B · US 10,729,685 B2 · ¶ 4
patent.fyi, US 2026/0355108 A1, claim 1, first published 2026-11-19T07:53:10-05:00, https://patent.fyi/US20260355108/, SHA-256 68134fdf152af35213764be46eb6acb253133cd4d197772349b2be41b90a008c